Plain-English translation of NCT06693323 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a supplement called AHCC in people who have been diagnosed with HPV-positive head and neck squamous cell carcinoma (a type of cancer in the head or neck area). The supplement is being given alongside the standard cancer treatments that you would normally receive. Researchers want to see if adding this supplement helps improve how well the treatment works and whether it's safe to use together with standard care.
Head and neck cancer can be aggressive, especially when it involves high-risk features like positive surgical margins or spread to nearby lymph nodes. This trial is exploring whether this medication might boost your body's natural defenses or improve treatment outcomes when used together with standard care.
You likely qualify if…
You likely don't qualify if…
You would take the supplement by mouth as a daily oral medication alongside your standard cancer treatment. The trial involves blood tests and imaging scans within 28 days before you start, and you'll need to have adequate organ function confirmed by lab work. The study is enrolling 34 people total at a single medical center (University of California, Irvine), and researchers will monitor both your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of California, Irvine
Enrollment target
~34 participants
Started
December 2024
Primary completion
December 2027
Age range
18 Years – 79 Years
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chao Family Comprehensive Cancer Center University of California, Irvine
Chao Family Comprehensive Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.